Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000002575 | SCV001226248 | pathogenic | Exostoses, multiple, type 2 | 2023-07-21 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 2471). This variant is also known as 784-787del. This premature translational stop signal has been observed in individual(s) with clinical features of multiple exostoses (PMID: 8782816). It has also been observed to segregate with disease in related individuals. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Val154Profs*115) in the EXT2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EXT2 are known to be pathogenic (PMID: 10679937, 19810120). |
Prevention |
RCV003415629 | SCV004108986 | pathogenic | EXT2-related disorder | 2023-05-15 | criteria provided, single submitter | clinical testing | The EXT2 c.454_457delCTGT variant is predicted to result in a frameshift and premature protein termination (p.Val154Profs*115). This variant has been previously reported in an individual with hereditary multiple osteochondromas (Table 2, Fusco et al. 2019. PubMed ID: 30806661). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Frameshift variants in EXT2 are expected to be pathogenic. This variant is interpreted as pathogenic. |
OMIM | RCV000002575 | SCV000022733 | pathogenic | Exostoses, multiple, type 2 | 1996-09-01 | no assertion criteria provided | literature only |